HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) All Versions of this Article: dc07-2105v1 31/7/1448    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Freeman, R. Articles by Emir, B. Search for Related Content PubMed PubMed Citation Articles by Freeman, R. Articles by Emir, B. Social Bookmarking                What's this?

Efficacy, safety and tolerability of pregabalin treatment of painful diabetic peripheral neuropathy: findings from 7 randomized, controlled trials across a range of doses

¹Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, U.S.A.
²Pfizer Global Pharmaceuticals, New York, NY

rfreeman{at}bidmc.harvard.edu

ABSTRACT

OBJECTIVE: to evaluate the efficacy, safety, and tolerability of pregabalin across the effective dosing range; to determine differences in the efficacy of TID and BID dosage schedules; and to use time to event analysis to determine the time to onset of a sustained therapeutic effect using data from 7 trials of pregabalin in painful diabetic neuropathy (DPN).

METHODS: Data were pooled across 7 double-blind, randomized, placebo-controlled trials using pregabalin to treat painful DPN with dosages of 150, 300, and 600 mg/d, administered TID or BID. Only 1 trial included all 3 of these dosages and TID dosing was used in 4. All studies shared fundamental selection criteria and treatment durations ranged from 5-13 weeks.

RESULTS: pooled analysis showed pregabalin significantly reduced pain and pain-related sleep interference associated with DPN (150, 300 and 600 mg/d administered TID vs placebo all P 0.007). Only the 600 mg/d dosage showed efficacy when administered BID (P 0.001). Pain and sleep interference reductions associated with pregabalin appear to be positively correlated with dosage; the greatest effect was observed in patients treated with 600 mg/d. Kaplan-Meier analysis revealed the median time to onset of a sustained (30% at end-point) 1-point improvement was 4 days in patients treated with pregabalin 600 mg/d; 5 days in patients treated with pregabalin 300 mg/d; 13 days in patients receiving pregabalin 150 mg/d; and 60 days in patients receiving placebo. The most common treatment-emergent adverse events were dizziness, somnolence and peripheral edema.

CONCLUSIONS: Treatment with pregabalin across its effective dosing range is associated with significant, dose-related improvement in pain in patients with DPN.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?